Why Bright Minds Biosciences Stock Topped the Market on Monday

Bright Minds Biosciences (NASDAQ: DRUG) is strengthening the team behind its latest investigational drug program, and investors expressed cautious optimism with the move. They pushed the clinical-stage biotech's shares up marginally (0.2%), on a Monday when the S&P 500 index dipped into the red with a 0.9% decrease. Less than two weeks after announcing the launch of a new program targeting the rare genetic disorder Prader-Willi Syndrome, Bright Minds said it's bringing in a quartet of seasoned experts to help with the effort. Image source: Getty Images.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool